Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Sara Hurvitz, MD, Discusses Trials on Tucatinib Therapy for HER2+ Metastatic Breast Cancer

Dr Hurvitz, University of California Los Angeles Jonsson Comprehensive Cancer Center, discusses the HER2CLIMB and enrolling phase 3 HER2CLIMB-02 trials examining tucatinib's activity and safety for treatment of patients with HER2-positive metastatic breast cancer and those with stable and active brain metastases, highlighted at the virtual San Antonio Breast Cancer Symposium.

Advertisement

Advertisement

Advertisement

Advertisement